1. Home
  2. CNTN vs RCEL Comparison

CNTN vs RCEL Comparison

Compare CNTN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$2.00

Market Cap

146.5M

Sector

Health Care

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$7.90

Market Cap

146.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
RCEL
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.5M
146.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
CNTN
RCEL
Price
$2.00
$7.90
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
700.3K
610.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
88.10
27.20
EPS
N/A
N/A
Revenue
N/A
$71,610,000.00
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.45
52 Week Low
$1.75
$3.22
52 Week High
$5.27
$8.55

Technical Indicators

Market Signals
Indicator
CNTN
RCEL
Relative Strength Index (RSI) 44.48 72.73
Support Level $1.75 $3.67
Resistance Level $3.80 N/A
Average True Range (ATR) 0.13 0.55
MACD 0.04 0.29
Stochastic Oscillator 77.94 82.11

Price Performance

Historical Comparison
CNTN
RCEL

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: